Open AccessThe treatment of acromegaly with long-acting octreotide: the effective control of disease activity and decrease of the tumour volume
Author(s) -
С. А. Догадин,
Margarita Dudina,
Л. А. Лобынцева
Publication year - 2012
Publication title -
problemy èndokrinologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 5
eISSN - 2308-1430
pISSN - 0375-9660
DOI - 10.14341/probl20125843-7
Subject(s) - octreotide , medicine , acromegaly , adjuvant , surgery , gastroenterology , somatostatin , urology , growth hormone , hormone
The objective of the present retrospective study was to evaluate the results of the long-term treatment of the patients suffering from active acromegaly with octreotide. It included a total of 48 patients at the age from 30 to 77 years (15 men and 33 women) of whom 18.7% and 81.2% presented with pituitary microadenoma and macroadenoma respectively. All the patients were given long-acting octreotide either as primary or as adjuvant therapy at a dose of 20-40 mg once every 28 days for 3 years. The treatment resulted in the remission in 9 (100%) patients having pituitary microadenoma and 9 (23%) ones with macroadenoma. By the end of the 3-year treatment period the clinically significant decease of the tumour volume was documented in 9 (100%) and 32 (82%) patients presenting with microadenoma and macroadenoma, respectively.